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Modified amino acid copolymers suppress myelin
basic protein 85–99-induced encephalomyelitis in
humanized mice through different effects on T cells
Zsolt Ille´s†‡, Joel N. H. Stern‡§, Jayagopala Reddy†, Hanspeter Waldner†, Marcin P. Mycko†¶, Celia F. Brosnan,
Stephan Ellmerich††, Daniel M. Altmann††, Laura Santambrogio‡‡, Jack L. Strominger§‡‡§§¶¶, and Vijay K. Kuchroo†§§
†Center for Neurologic Diseases, Harvard Institute of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; §Department of
Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138; Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461;
††Department of Infectious Diseases, Imperial College, London WC1E 6BT, United Kingdom; and ‡‡Department of Cancer Immunology and AIDS,
Dana–Farber Cancer Institute, Boston, MA 02115
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A humanized mouse bearing the HLA-DR2 (DRADRB1*1501) pro-
tein associated with multiple sclerosis (MS) and the myelin basic
protein (MBP) 85–99-specific HLA-DR2-restricted T cell receptor
from an MS patient has been used to examine the effectiveness
of modified amino acid copolymers poly(F,Y,A,K)n and poly-
(V,W,A,K)n in therapy of MBP 85–99-induced experimental auto-
immune encephalomyelitis (EAE) in comparison to Copolymer 1
[Copaxone, poly(Y,E,A,K)n]. The copolymers were designed to
optimize binding to HLA-DR2. Vaccination, prevention, and treat-
ment of MBP-induced EAE in the humanized mice with copolymers
FYAK and VWAK ameliorated EAE more effectively than Copoly-
mer 1, reduced the number of pathological lesions, and prevented
the up-regulation of human HLA-DR on CNS microglia. Moreover,
VWAK inhibited MBP 85–99-specific T cell proliferation more effi-
ciently than either FYAK or Copolymer 1 and induced anergy of
HLA-DR2-restricted transgenic T cells as its principle mechanism. In
contrast, FYAK induced proliferation and a pronounced production
of the antiinflammatory T helper 2 cytokines IL-4 and IL-10 from
nontransgenic T cells as its principle mechanism of immunosup-
pression. Thus, copolymers generated by using different amino
acids inhibited disease using different mechanisms to regulate T
cell responses.
multiple sclerosis  DRB1*1501  microglia  CNS  autoimmunity
Multiple sclerosis (MS) is an autoimmune disease mediated byCD4 T cells reactive to antigens of the myelin sheath,
resulting in inflammation and demyelination in the CNS (1). Myelin
basic protein (MBP), one of the major myelin antigens, has long
been presumed to be an important autoantigen, based on the
animal model of MS, experimental autoimmune encephalomyelitis
(EAE). Several lines of evidence suggest that MBP-specific T cells
are involved in the pathogenesis of MS: (i) The frequency of
MBP-specific T cells is increased in the peripheral blood of patients
with MS (2). (ii) A number of studies have shown persistent clonal
expansion of MBP-specific T cells either in the peripheral blood or
in the cerebrospinal fluid of MS patients (3–6). (iii) T cell infiltrates
of MS plaques in the CNS and MBP-specific T cell clones share
significant homologies in their T cell receptor (TCR) CDR3
sequences, implying that MBP-specific T cells contribute to the
neuropathology of MS (7). (iv) An increase in the frequency and
affinity of MBP-reactive T cells in the peripheral blood was shown
to exacerbate disease and increase the number of plaques in the
CNS of MS patients (8).
Human HLA-DR2, and specifically that encoded by the
DRADRB1*1501 alleles, is thought to be important in the
presentation of the immunodominant epitope MBP 85–99
(9, 10). Although the association of the human MHC class II
(MHC II) locus with MS has consistently been observed in
genome-wide scans (11), an association of the HLA-DR2, DQ6
haplotype, including the DRB1*1501 allele, with susceptibility to
MS has been suggested in several population- and family-based
studies (12). The importance of the DRB1*1501-associated
MBP 85–99 epitope in the pathogenesis of MS has been partic-
ularly proposed based on data that, in MS lesions, the microglia
macrophages were positive for the HLA-DR2MBP 85–99 com-
plex detected by a monoclonal antibody specific for this complex
(13). Moreover, mice transgenic (tg) for HLA-DR2 and the TCR
from an MS patient develop EAE spontaneously in 6–12 months
and the disease appearance can be accelerated by immunization
with MBP 85–99 (14).
Several clinical attempts have been made to interfere with the
MHC IIMBP 85–99TCR trimolecular complex with varying
effectiveness (8, 15–19). Currently, Copolymer 1 (Cop1, Copaxone,
glatiramer acetate) is used in MS patients as an immunomodulator
(20–22). Cop1 is a random polypeptide synthesized from four
amino acids, L-tyrosine, L-glutamic acid, L-alanine, and L-lysine
[poly(Y,E,A,K)n], in a specific molar ratio of 1.0, 1.4, 4.2, and 3.4,
respectively. Although the mechanism of action of Cop1 is not fully
understood, several immunologic effects have been suggested (23,
24). These include competition of Cop1 with the immunodominant
MBP 85–99 peptide for binding to DRB1*1501 and competition of
MHC IICop1 and MHC IIMBP complexes for binding to the
TCR (23, 25–28). Cop1 has also recently been shown to polarize T
cells into a T helper 2 (Th2) phenotype. Splenocytes from Cop1-
immunized mice transfer protection against EAE, and Cop1-
specific Th2 cells capable of secreting IL-4 and IL-10 dominate in
the CNS of protected mice (29). Similarly, MS patients treated with
Cop1 have Cop1-specific T cells with a Th2 phenotype (30).
Although widely used in the treatment of MS, Cop1 reduces
the frequency of relapses by only 30% (21). We hypothesized
that by improving the binding capacity of copolymers to HLA-
DR2 relative to MBP 85–99, it may be possible to develop a more
effective immunomodulator. Several random 4-aa copolymers
were designed based on the knowledge of anchor residues used
by the immunodominant MBP 85–99 epitope that bind to the
DRB1*1501-encoded molecule. To determine the in vivo and in
vitro effect of these copolymers, a humanized double-tg mouse
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expressing the human MHC II molecule encoded by DRA
DRB1*1501 and an MS patient-derived MBP 85–99-specific
TCR, similar to that recently described (14), was used.
Here we show that two copolymers, namely poly(F,Y,A,K)n and
poly(V,W,A,K)n, significantly reduced the severity of MBP 85–99-
induced EAE in the humanized mice more effectively than Cop1
[poly(Y,E,A,K)n] in three different modalities of administration–
vaccination, prevention, and treatment. In addition we show that
several different mechanisms are involved in immunomodulation
by these copolymers and that distinct copolymers may inhibit the
disease by different mechanisms.
Materials and Methods
Copolymers, MBP 85–99 Peptide, and HLA-DR2. Copolymers are
described in the companion paper (31). Peptides were synthesized
on an Applied Biosystems Peptide Synthesizer and purified by
reverse-phase HPLC. Peptide sequences were MBP 85–99, ENPV-
VHFFKNIVTPR, either unlabeled or with biotin linked to the N
terminus by the spacer SGSG and free acid at the C terminus.
Peptide binding to HLA-DR2 (DRADRB1*1501) isolated from
S2 insect cells by affinity chromatography was competed by copol-
ymers or MBP 85–99 as described (22, 32). The effects of copoly-
mers on T cell proliferation and cytokine measurements were
carried out as described (22, 31).
Humanized tg Mice. Humanized double tg mice expressing both
HLA-DR2 (DRADRB1*1501) and the TCR from the MS patient
Ob in an A0 background were generated by standard techniques
described in more detail in Supporting Text, which is published as
supporting information on the PNAS web site.
Prepulse Assay and Induction of Anergy. Assays were performed as
described with a few modifications (23, 26). To induce anergy,
CD3 T cells were enriched from spleens of humanized tg mice by
using Mouse T Cell Enrichment kit (R & D Systems). A total of 1
106 T cells and 2  106 irradiated splenic cells of humanized mice
were incubated for 48 h in 24-well culture plates in the presence of
copolymers (0.01, 0.1, or 1 gml). After resting for 2 days, viable
cells were isolated by centrifugation over Ficoll-Hypaque, and 4 
104 cells were restimulated with 20gml MBP 85–99 peptide in the
presence of 5 105 irradiated antigen-presenting cells (APCs). The
cells were pulsed with 3H 2 days later, and the proliferative response
was measured after 16 h by [3H]thymidine incorporation.
To examine competition for the MBP 85–99-specific TCR, 3 
106 per ml irradiated splenocytes from the humanized mice were
incubated with 2 gml MBP 85–99 peptide at 37°C for 3 h. Cells
were washed, and 3  105 cells per well were cultured in 96-well
microculture plates with 2 104 per well fluorescence-activated cell
sorted tg hV2CD4 or non-tg hV2CD4 T cells. Copolymers
FYAK or VWAK were added at 5 g and 20 gml concentration
with the T cells.
Antibodies Used for Surface Marker Staining and Sorting by Flow
Cytometry of tg and Endogenous (Non-tg) T Cells. A total of 5 105
lymphocytes from humanized mice were stained with anti-CD69-
phycoerythrin (PE) (Pharmingen), anti-CD4-allophycocyanin
(Pharmingen), anti-human HLA-DR-PE (Pharmingen), or anti-
human V2-FITCPE (Immunotech) for 30 min on ice in 1 PBS
containing 2% FCS. Cells were washed and acquired by flow
cytometry using FACSFlow cytometer (Becton Dickinson) and
analyzed by FLOWJO software (Treestar, Amersham Pharmacia).
Labeled T cells were sorted by FACSVantage SE (Becton Dick-
inson). The purity of sorted T cells was usually 98–99%.
Immunization Procedures, EAE Induction, and Treatment of Mice with
Copolymers. Female humanized tg mice were immunized with 150
g of MBP 85–99 peptide or 500 g of FYAK, VWAK, or Cop1
in complete Freund’s adjuvant (CFA) s.c. in a volume of 200 l in
the inguinal and axillary areas, and mice were monitored as
described (22, 31).
Results
Synthetic Copolymers FYAK and VWAK Compete with MBP 85–99 for
Binding to HLA-DR2 (DRB1*1501). Based on the knowledge of anchor
residues used by the immunodominant MBP 85–99 epitope to bind
to HLA-DR2, two random copolymers, FYAK and VWAK, were
designed. To investigate whether these copolymers compete with
MBP 85–99 peptide for binding to HLA-DR2 (encoded by HLA-
DRADRB1*1501), competitive binding assays were performed by
using biotinylated MBP 85–99 and unlabeled copolymers at varying
concentrations. Both copolymers were more efficient than Cop1 in
competing with MBP 85–99 for binding to HLA-DR2, and VWAK
competed even better than FYAK (Fig. 1).
Copolymers Inhibit the in Vitro HLA-DR2-Restricted MBP 85–99-
Specific T Cell Response. To determine whether the copolymers
could also inhibit presentation of the MBP 85–99 peptide to
HLA-DR2-restricted T cells, TCR transfectants (Ob8073 and
Hy1B) were used. The TCRs introduced into the transfectants
were derived from MBP 85–99-specific HLA-DR2-restricted T
cell lines established from patients Ob (DRB1*1501) and Hy
(DRB1*1602). FYAK and VWAK inhibited IL-2 production
from both MBP 85–99-specific Hy1B and Ob 8073 TCR trans-
fectants much better than Cop1, when MGAR (human lympho-
blastoid B cell line that expresses DRB1*1501) was used as the
APC (Fig. 6, which is published as supporting information on the
PNAS web site). FYAK and VWAK also inhibited proliferation
of both transfectants. As a control, when L cell transfectants
expressing HLA-DR2a (encoded by DRADRB5*0101) were
used as APCs, no proliferative response was observed, demon-
strating that both Ob8073 and Hy1B transfectants were re-
stricted by HLA-DR2b (encoded by HLA-DRADRB1*1501)
(data not shown). Thus, the copolymers were able to reduce the
in vitro MBP 85–99-specific T cell response in a HLA-DR2-
restricted fashion.
Recently Developed Copolymers FYAK and VWAK Ameliorate MBP
85–99 Peptide-Induced EAE in Humanized tg Mice. Next, the effect of
the copolymers was examined in vivo on the development of EAE.
A double tg humanized mouse model generated by using human
TCR and the HLA-DR2 (DRB1*1501) molecule was used. In this
model of MS, the tg mice express the rearranged TCR  and 
chains of an MBP 85–99-specific T cell clone (ObA1.12) derived
from an MS patient (Ob) and the DRB1*1501 gene together with
Fig. 1. Recently developed copolymers compete for binding to human
HLA-DR2 (DRB1*1501). Inhibition of biotinylated MBP 85–99 binding to HLA-
DR2 molecules by these copolymers. Recombinant HLA-DR2 molecules were
incubated with 0.13 M biotinylated MBP 85–99 alone or in the presence of
excess unlabeled competitors at the indicated concentrations.
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the DRA gene in a mouse strain lacking expression of endogenous
mouse MHC II molecules.
EAE was induced by immunizing the humanized tg mice with
MBP 85–99 in CFA. The majority of mice showed the clinical signs
of EAE as early as day 7. The disease was manifested by severe
paralysis (score 3–4) and was fatal in one-third of the mice. The
mice that survived developed a chronic unremitting paralysis. In
contrast, in mice coimmunized with copolymers and MBP 85–99,
the severity of EAE was significantly reduced. The inhibition of
disease was most pronounced in groups of mice coimmunized with
copolymers FYAK or VWAK. None of the animals died in these
two groups. Cop1 and a third copolymer, VYAK, which were less
effective in the in vitro assays, also reduced the signs of EAE, but
not as effectively as VWAK or FYAK (Fig. 2A and Table 1, which
is published as supporting information on the PNAS web site).
VYAK has not been studied further. Similar results were obtained
when mice were preimmunized with FYAK or VWAK 2 days
before immunization with the encephalitogenic MBP 85–99 pep-
tide (Fig. 2B).
Next the effect of FYAK and VWAK on already established
EAE was investigated in comparison to a group of mice treated
with Cop1. The disease was induced with MBP 85–99, and at the
first sign of disease, the animals were randomized and treated s.c.
with 150 g of soluble FYAK, VWAK, or Cop1 in PBS
mannitol. The treatment was then repeated daily for 1 week. As
compared to untreated mice, which developed significant EAE
with peak disease around days 15–20, FYAK and VWAK
significantly reduced the severity of disease in both the acute and
chronic phases. VWAK was slightly more effective than FYAK,
and both were more efficient than Cop1 (Fig. 2C and Table 1).
Recently Developed Copolymers FYAK and VWAK Reduce Inflamma-
tion and Demyelination. Analysis of CNS tissues from animals
immunized with MBP 85–99 alone showed perivascular mono-
nuclear infiltrates at all levels of the brain and spinal cord. In
animals coimmunized with FYAK or VWAK and MBP 85–99,
the perivascular cuffs were smaller, the infiltration into the
parenchyma was less marked, and the number of inflammatory
foci was significantly reduced compared to the MBP 85–99-
induced disease (MBP 85–99, 28 3; FYAK, 13.3 2.2; VWAK,
16.3 0.9) (Fig. 7, which is published as supporting information
on the PNAS web site). Despite extensive inflammation, the
demyelination was mild in the MBP 85–99-induced disease, and
was further reduced in the copolymer-treated mice (data not
shown).
Coimmunization with MBP 85–99 and FYAK or VWAK Differentially
Alters the Recall T Cell Response to MBP 85–99 in Vitro. To test the
possibility that a reduced or altered MBP 85–99-specific T cell
response in vivo might be responsible for the amelioration of
EAE in humanized tg mice, the tg mice were coimmunized with
MBP 85–99 and FYAK, VWAK, or Cop1, and the recall
response to MBP 85–99 peptide was examined 7 days later in
splenocyte cultures (Fig. 3). Coimmunization with VWAK mark-
edly reduced the proliferative response to MBP 85–99. On the
other hand, FYAK and Cop1 barely altered the proliferative
response to MBP 85–99 in tg splenocytes (Fig. 3A).
Cytokine secretion was measured by ELISA in the above cultures
restimulated with 25 gml MBP 85–99 peptide. In splenocyte
cultures established from mice immunized with MBP 85–99 peptide
alone, IL-2, IFN-, and a small amount of IL-4 were produced, but
no IL-10 was produced. Splenocytes of mice coimmunized with
FYAK produced large amounts of IL-4 and IL-10 in response to
MBP 85–99, whereas IFN- production was moderately reduced. In
contrast, in splenocyte cultures of mice coimmunized with VWAK,
IFN- production was markedly suppressed, but the amount of IL-4
and IL-10 was lower in comparison to FYAK. In cultures derived
from Cop1-coimmunized mice, no IL-4 and only a low level of IL-10
were produced, whereas IFN- secretion was only moderately
reduced (Fig. 3B).
Thus, although VWAK reduced proliferation and IFN-
production of splenocytes, FYAK induced IL-4 and IL-10 pro-
duction more efficiently. The two copolymers appear to act
through different mechanisms. These data raised several ques-
tions: Are other mechanisms in addition to MHC II blockade
also responsible for the reduced MBP-specific proliferative
response and reduced IFN- production in the case of VWAK?
In the case of FYAK particularly, are the cytokines IL-4 and
IL-10 derived from the tg MBP-specific T cells or from endog-
enous copolymer-specific T cells?
Copolymers VWAK and FYAK Induce Anergy andor Have an Antag-
onistic Effect on the Humanized MBP 85–99-Specific tg TCR. Cop1 was
able to induce unresponsiveness of MBP 85–99-specific and
copolymer-reactive T cells (23, 26, 33). To examine whether all
the copolymers are able to induce unresponsiveness, enriched
CD3 T cells from humanized tg mice were cultured for 48 h
with low-dose FYAK, VWAK, or Cop1 in the presence of
Fig. 2. Recently developed copolymers ameliorate MBP 85–99-induced EAE
in humanized tg mice. (A) Humanized tg mice were immunized with 150
gml MBP 85–99 in CFA or coimmunized with 500 gml FYAK, VWAK,
VYAK, or Cop1 and 150gml MBP 85–99 in CFA. (B) Humanized tg mice were
immunized with 500 gml copolymers FYAK, VWAK, or Cop1 2 days before
disease was induced with 150 gml MBP 85–99 in CFA. (C) EAE was induced
by immunization with 150 gml MBP 85–99 followed by administration of
150 g FYAK or VWAK s.c. for 7 consecutive days beginning at the first sign
of disease. Data shown represent one of two to three separate experiments of
four to six mice per group.
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irradiated splenocytes from the tg mice. After 2 days of resting,
viable cells were restimulated with fresh, MBP 85–99-pulsed
irradiated splenocytes. The MBP 85–99-specific proliferative
response was effectively reduced at 0.01 gml concentration
only by VWAK, although all of the copolymers were able to
significantly reduce it at 0.1 gml (Fig. 4A). The percentage of
CD4 T cells was unaltered and, thus, apoptosis of T cells at
these concentrations was unlikely (data not shown). Preincuba-
tion with 0.1 and 0.01 gml MBP 85–99 peptide did not induce
anergy of tg T cells. Neither were copolymers able to induce
anergy of tg T cells of another specificity, indicating that this
action required the MBP 85–99-specific TCR (data not shown).
Antagonistic effects of the copolymers for the MBP 85–99-
specific TCR was tested in a prepulse assay (26). First, irradiated
tg splenocytes were incubated with 2 gml MBP 85–99 for 3 h
at 37°C to saturate HLA-DR2 (DRB1*1501). Then, sorted tg
hV2CD4 T cells were added to the splenocytes in the
absence or presence of FYAK or VWAK. When incubated with
copolymers, tg T cells proliferated significantly less. VWAK
showed strongest inhibition whereas FYAK showed only modest
inhibition of T cell proliferation (Fig. 4B). Endogenous, non-tg
V2CD4 T cells from naı¨ve mice did not proliferate to either
MBP or copolymers (data not shown).
Thus, in addition to competition for binding to HLA-DR2,
both induction of T cell unresponsiveness and TCR antagonism
may also contribute to the in vivo effect of these copolymers.
Moreover, different effects on T cell responses of the individual
copolymers were again noted. VWAK was most effective in
inducing both T cell anergy and antagonism.
Immunization with Recently Developed Copolymers FYAK and VWAK
Differentially Induces Copolymer-Reactive Endogenous Th2 Cells. Al-
though the reduced T cell response in the case of coimmunization
with VWAK could be explained by the combined effects of MHC
II competition, induction of anergy, and competition for TCR, it
was not clear whether these mechanisms were responsible for the
inhibiting effects of FYAK. Because Cop1 has been shown to
induce responding Th2 cells (30), cytokine production induced by
the copolymers in the tg and non-tg T cells was examined. The
tg T cells contribute about half of the T cell repertoire in the
humanized mice, so the effect of copolymers on the non-tg T cell
repertoire had to be considered.
First, to test whether copolymers can prime copolymer-reactive
T cells in this model, humanized tg mice were immunized with
either FYAK or VWAK, and the T cell response to the corre-
sponding copolymer was examined in splenic cultures 7 days later.
The proliferative response was higher in spleen cells from FYAK-
than from VWAK- immunized mice, and FYAK also induced more
IL-4 and IL-10 (data not shown). However, it was not clear whether
the copolymers primed endogenous T cells to produce Th2 cyto-
kines or cross-reacted with the MBP 85–99-specific tg TCR and
induced cytokine deviation as partial TCR agonists. To address this
question, non-tg (hV2CD4) and tg (hV2CD4) T cells were
separated by flow cytometry from mice immunized with FYAK or
VWAK alone. Both fractions were then restimulated in vitro by the
corresponding copolymer or with MBP 85–99 peptide. MBP 85–99
induced significantly higher proliferation of tg T cells as expected.
However, FYAK and VWAK primed the non-tg T cells (Fig. 5A).
The proliferative response of non-tg T cells was significantly higher
to FYAK than to VWAK. In addition, endogenous non-tg hV2
T cells produced more IL-4 and IL-10 in response to copolymers
particularly notable in IL-10 production after immunization with
FYAK (Fig. 5B1). By contrast, the tg hV2 T cells produced a
large amount of IL-2, and particularly IFN-, in response to MBP
85–99 (Fig. 5B2). Thus, although VWAK was more effective in
competing for MHC II and for the MBP-specific tg TCR in which
it induced anergy, FYAK primed non-tg copolymer-specific T cells
to produce the Th2 cytokine IL-10 much more effectively.
Fig. 3. Coimmunization with copolymers alters the recall response to MBP
85–99 peptide in vitro. (A) Humanized tg mice were immunized with 150
gml MBP 85–99 or coimmunized with 500gml Cop1, FYAK, or VWAK and
150 gml MBP peptide in CFA. In vitro proliferative response of splenocytes
to MBP 85–99 is shown at day 7. (B) Splenocytes from mice immunized with
MBP 85–99 or coimmunized with MBP 85–99 and copolymers were incubated
with different concentration of MBP 85–99 peptide, and cytokine production
was analyzed by ELISA.
Fig. 4. Antagonistic effects of copolymers FYAK and VWAK on tg MBP
85–99-specific T cells. (A) Anergy. Enriched CD3 T cells and irradiated spleno-
cytes of the humanized mice were incubated in the presence of copolymers at
the indicated concentrations. Cells were rested for 48 h, and viable cells were
restimulated with 20 gml MBP 85–99 peptide. Data are shown as cpm of
triplicates. (B) TCR antagonism. Irradiated splenocytes of humanized tg mice
were incubated with 2gml MBP 85–99 peptide. Cells were then washed and
subsequently cultured with sorted hV2CD4 cells in the presence of FYAK
or VWAK at the indicated concentrations. Data are shown as mean cpm of
triplicates.
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FYAK Induces Cytokine Deviation of tg MBP 85–99-Specific T Cells.
Although both FYAK and VWAK copolymers primed essentially
non-tg T cells, a low-grade proliferation of tg T cells was observed
in response to FYAK and less to VWAK in immunized mice (Fig.
5A). Because the purity of sorted fractions was 98–99%, this
response might suggest cross-reactivity of FYAK with the MBP-
specific TCR. Therefore, the question whether this cross-reactive
response was characterized by altered cytokine production as
compared to the MBP 85–99-induced response was examined.
Cytokine production of tg T cells to MBP 85–99 was characterized
by high levels of IFN-. In contrast, tg T cells from mice immunized
with FYAK or VWAK produced low amounts of IL-10 but no
IFN- in response to copolymers. This IL-10 production of tg T cells
was significantly higher in FYAK-immunized mice (Fig. 5B2).
Although both tg and non-tg subsets appeared to contribute to the
IL-10 production, IL-4 was produced predominantly by endoge-
nous non-tg T cells.
Discussion
The availability of a humanized mouse model of MS has made
it possible to study two recently developed copolymers, VWAK
and FYAK, in comparison to Cop1 (a drug currently in use for
treatment of MS) in an EAE animal model that is as close to MS
as is presently possible. This mouse is tg for the major MS
susceptibility gene HLA-DR2 (DRB1*1501) as well as for the
TCR from an MBP 85–99-specific, HLA-DR2-restricted T cell
from an MS patient. In three different modalities of adminis-
tration of copolymers in this mouse, termed vaccination, pre-
vention, and treatment, the order of effectiveness of the copol-
ymers was VWAK  FYAK  Cop1 (Fig. 2).
Studies of the mechanism by which these copolymers modulate
the EAE in this model have revealed the following. First, not
surprisingly because the two copolymers, VWAK and FYAK, were
designed to optimize binding to HLA-DR2, both bound more
effectively than Cop1 (Fig. 1) and both inhibited the proliferation
of and IL-2 secretion by MBP-specific TCR transfectants (Fig. 6).
The amino acid composition of Cop1 (YEAK) is not optimal to
block binding of MBP 85–99 to MHC II, because Y (tyrosine) has
a side chain too large to bind in the small P1 pocket of HLA-DR2
(encoded by HLA-ADRB1*1501); A (alanine) is too small,
whereas E (glutamate) and K (lysine) are too hydrophilic to bind in
the hydrophobic P1 pocket (9, 22, 32, 34). Thus, replacing the Y
andor E was hypothesized to improve binding to HLA-DR2.
Indeed, the strongest effect was seen when E was replaced with F
(phenylalanine) (FYAK), which hypothetically fits better into the
small P1 pocket, or when both Y and E were replaced by V (valine)
and W (tryptophane) (VWAK), which may possibly improve
binding to both P1 (V) and P4 pockets (W). K was retained for
solubility and because it is a principal stimulating TCR contact
residue at P5 of MBP 85–99.
Other studies of mechanism focused on splenocytes derived from
immunized tg mice. Initially, splenocytes of mice immunized with
MBP 85–99 or coimmunized with this same peptide together with
a copolymer were examined. The marked enhancement of prolif-
eration induced by MBP 85–99 was reduced by VWAK, but only
slightly affected by FYAK or Cop1. Measurement of cytokine
production in the supernatant of these same cultures showed that
splenocytes from tg mice immunized with MBP 85–99 alone
produced IL-2 and INF-, but little IL-4 and no IL-10. By contrast,
splenocytes of animals coimmunized with FYAK produced, in
response to MBP 85–99, large amounts of IL-4 and IL-10 and a
reduced amount INF-, particularly at low doses of antigen. Co-
immunization with VWAK resulted in a more striking reduction of
INF- production, but secretion of only modest amounts of IL-4
and IL-10. Cop1 reduced INF- production similarly to FYAK, but
no IL-4 and only modest amounts of IL-10 were produced. Thus,
the three copolymers tested have distinct effects on cytokine
production by splenocytes, with FYAK clearly resulting in produc-
tion of the largest amounts of Th2 cytokines. Further studies of
anergy induction and TCR antagonism again revealed difference
among the copolymers, with VWAK clearly more effective than
either FYAK or Cop1 in both types of assays (Fig. 4).
Finally, this model permitted separation of two types of spleno-
cytes from mice immunized with FYAK or VWAK alone, the tg
hV 2CD4 and endogenous non-tg hV 2CD4 T cells. This
separation made it possible to separately analyze the effects of
copolymers on the MBP 85–99-specific tg T cell response and on the
non-tg, endogenous T cell repertoire in the same model. As
expected, tg T cells that carried a TCR with specificity for the
HLA-DR2MBP 85–99 complex proliferated vigorously to MBP
85–99 presented by an HLA-DR2-bearing APC (Fig. 5A). By
contrast, the non-tg T cells were the cells that proliferated to FYAK
or VWAK, but the response to the latter was quite small, as had
already been seen in studies of splenocytes. In parallel, production
of IFN- on stimulation with MBP 85–99 was mainly due to the tg
T cells, whereas production of IL-4 and IL-10 by cells from FYAK-
or VWAK-treated mice, particularly the former, was derived mainly
from the non-tg T cells (Fig. 5B). In addition, as with splenocytes,
FYAK was much more effective in stimulating cells that produce
IL-10 than VWAK. Furthermore, FYAK induced some IL-10
production also by the tg T cells (Fig. 5B), suggesting that FYAK
may cross-react with the MBP 85–99-specific TCR, and alter the
cytokine production of tg T cells (immune deviation). Alternatively,
FYAK-specific Th2 cells could influence activation of the tg T cells.
The properties of FYAK- and VWAK-specific T cells as regulatory
Fig. 5. Recently developed copolymers induce a copolymer-reactive non-tg
T cell response and immune deviation of tg MBP 85–99-specific T cells. (A)
Humanized mice were immunized with 500 gml FYAK or VWAK in CFA.
Lymph nodes and spleen cells were isolated 7days later,and hV2CD4 and
hV2CD4were sorted. Fractionated T cells were restimulated with 25gml
MBP 85–99 peptide (Left) or 25gml of the corresponding copolymer (Right).
(B) Non-tg hV2CD4 (B1) and tg hV2CD4 T cells (B2) from mice immu-
nized with FYAK or VWAK were stimulated with MBP 85–99 or the corre-
sponding copolymer, and cytokine production was analyzed by ELISA.
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T cells were clearly demonstrated in the companion paper by using
adoptive transfer experiments (31). Furthermore, expression of
HLA-DR2 on microglia in the CNS of humanized mice coimmu-
nized with copolymers and MBP 85–99 was not observed by
immunohistochemistry, whereas it was detected in the CNS of mice
immunized only with MBP 85–99. These results were also comple-
mented by in vitro studies showing that copolymers alone had no
effect on the expression of HLA-DR2 by microglia in culture (data
not shown). Thus, the possibility that this modulation of expression
in vivo may be due to an altered inflammatory environment in the
CNS induced by coimmunization with copolymers requires further
investigation.
Thus, two important points are derived from these studies of
mechanisms. First, a variety of mechanisms operate to ameliorate
EAE in humanized tg mice immunized with MBP 85–99 and
various copolymers. First of all, binding of the copolymers to the
HLA-DR2 protein on the tg APC has been greatly enhanced. The
other effects observed are all necessarily derived from this primary
binding event, and thus, enhanced binding may contribute impor-
tantly to the protective effects in the EAE model. FYAK and
VWAK are more efficient binders than Cop1, as expected, because
they were designed for this purpose. Second, the three different
copolymers studied differ in the extent to which they stimulated the
other mechanisms. FYAK was clearly most effective in inducing
non-tg T cells that proliferated and secreted, particularly, the Th2
cytokine IL-10, which is known to have a suppressive effect on
autoimmune diseases (35). However, VWAK was the most effective
copolymer in inducing T cell anergy and in reducing IFN- pro-
duction by MBP 85–99-stimulated splenocytes. Both of the copol-
ymers were superior to Cop1 in ameliorating disease and in
stimulating those mechanisms that may be important in this effect.
Finally, it may be useful to compare the two EAE models studied
in this and the accompanying paper (31). The humanized mouse
model allowed examination of the effect of copolymers on the
MBP-specific and nonspecific T cell responses in the context of a
human trimolecular complex. However, using SJLJ mice, the
effect of copolymers on T cells specific to another major myelin
protein, PLP, presented by a different MHC II (H-2s) could be
studied. Although the T cell repertoire is restricted in the human-
ized tg mouse, the SJLJ mice encompass a broad T cell repertoire.
This fact facilitated establishment of T cell lines, and performing of
adoptive transfer experiments to test the efficacy of copolymer-
specific T cells in vivo. Interestingly, although VWAK and FYAK
were designed to optimize binding to HLA-DR2 present in the
double tg mouse, they also bound more effectively to the I-AS
protein in the SJLJ mouse than Cop1. The amelioration of disease
in the two different mouse models was similar in the three types of
studies used, vaccination, prevention, and treatment, in the same
order of effectiveness, VWAK FYAK Cop1. A single notable
difference in the mechanism in the two models was observed.
Although VWAK effectively induced anergy of MBP 85–99-
specific HLA-DR2-restricted T cells in the double tg humanized
mouse, it did not do so in the PLP139–151-specific I-AS-restricted
T cells of the SJLJ mouse. Both studies suggest the possibility that
the copolymers VWAK and FYAK may be effective in the treat-
ment of MS.
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